Intelligent Bio Solutions Inc. (NASDAQ:INBS) Short Interest Update

Intelligent Bio Solutions Inc. (NASDAQ:INBS) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 420,600 shares, a growth of 13.9% from the October 15th total of 369,400 shares. Currently, 9.8% of the company’s stock are sold short. Based on an average trading volume of 1,740,000 shares, the days-to-cover ratio is currently 0.2 days.

Intelligent Bio Solutions Stock Performance

NASDAQ:INBS traded up $0.03 on Monday, reaching $1.51. The stock had a trading volume of 17,270 shares, compared to its average volume of 1,455,954. The company has a 50-day moving average of $1.68 and a 200 day moving average of $1.75. Intelligent Bio Solutions has a 12-month low of $1.00 and a 12-month high of $11.70.

Intelligent Bio Solutions (NASDAQ:INBS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.17). Intelligent Bio Solutions had a negative return on equity of 147.50% and a negative net margin of 1.19%. The business had revenue of $872.29 million during the quarter. On average, research analysts expect that Intelligent Bio Solutions will post -1.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Intelligent Bio Solutions stock. Virtu Financial LLC purchased a new position in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 12,537 shares of the company’s stock, valued at approximately $53,000. Virtu Financial LLC owned approximately 0.40% of Intelligent Bio Solutions as of its most recent filing with the SEC. Hedge funds and other institutional investors own 32.97% of the company’s stock.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.